Viridian Therapeutics, Inc.\DE (VRDN) Gross Margin (2013 - 2016)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Gross Margin came in at 35.95% in Q4 2016, down 6676.0% year-on-year from 0.55% in Q1 2016, and down 199.86% quarter-over-quarter from 36.0% in Q3 2016.
Viridian Therapeutics, Inc.\DE (VRDN) Gross Margin (2013 - 2016) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Gross Margin history runs 4 years deep, the most recent figure standing at 35.95% for Q4 2016.
- On a quarterly basis, Gross Margin fell 6676.0% year-over-year to 35.95% in Q4 2016; TTM through Dec 2016 was 26.72%, a 2.0% decrease from a year earlier, with the FY2016 full-year figure at 284.31%, down 28691.0% from the prior year.
- Gross Margin eased to 35.95% in Q4 2016 per VRDN's latest filing, from 36.0% in the prior quarter.
- Across five years, Gross Margin topped out at 56.78% in Q3 2015 and bottomed at 35.95% in Q4 2016.
- The 4-year median for Gross Margin is 34.5% (2014), against an average of 25.79%.
- Across the five-year window, Gross Margin soared 5004 bps in 2015 and plunged 6676 bps in 2016, its largest moves.
- Year by year, Gross Margin stood at 50.35% in 2013, then sank by 138 bps to 19.24% in 2014, then jumped by 260 bps to 30.8% in 2015, then plunged by 217 bps to 35.95% in 2016.
- Per Business Quant, the three latest VRDN Gross Margin figures stand at 35.95% (Q4 2016), 36.0% (Q3 2016), and 43.68% (Q2 2016).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -35.95% |
| Sep 30, 2016 | 36.00% |
| Jun 30, 2016 | 43.68% |
| Mar 31, 2016 | 31.41% |
| Dec 31, 2015 | 30.80% |
| Sep 30, 2015 | 56.78% |
| Jun 30, 2015 | 7.63% |
| Mar 31, 2015 | -17.83% |
| Dec 31, 2014 | -19.24% |
| Sep 30, 2014 | 51.92% |
| Jun 30, 2014 | 41.15% |
| Mar 31, 2014 | 33.00% |
| Sep 30, 2013 | 50.35% |
| Jun 30, 2013 | 51.33% |